Dr. Leibovich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-284-4951
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2001 - 2002
- Indiana University School of MedicineFellowship, Minimally Invasive Urologic Surgery, 2001 - 2001
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Urology, 1995 - 2001
- Albany Medical CollegeClass of 1995
- Cornell UniversityBA, Biochemistry, 1984 - 1989
Certifications & Licensure
- CA State Medical License 2001 - Present
- IA State Medical License 2021 - 2025
- MN State Medical License 1996 - 2025
- SD State Medical License Active through 2025
- AZ State Medical License 1997 - 1998
- American Board of Urology Urology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
- Distinguished Mayo Clinician Award Mayo Clinic, 2015
- Andrew C. Novick Award Kidney Cancer Association, 2014
- Join now to see all
Clinical Trials
- Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer Start of enrollment: 2003 Aug 01
- Exisulind Versus Placebo After Surgical Removal of the Prostate Start of enrollment: 2003 Feb 01
- Exisulind Prior to Radical Prostatectomy Start of enrollment: 2002 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 557 citationsRenal Mass and Localized Renal Cancer: AUA GuidelineSteven C. Campbell, Robert G. Uzzo, Mohamad E. Allaf, Eric B Bass, Jeffrey A. Cadeddu
The Journal of Urology. 2017-09-01 - 27 citationsDetectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic SignificanceShomik Sengupta, Carl M. Christensen, Horst Zincke, Jeffrey M. Slezak, Bradley C. Leibovich
The Journal of Urology. 2006-08-01 - 687 citationsTumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.R. Houston Thompson, Susan M. Kuntz, Bradley C. Leibovich, Haidong Dong, Christine M. Lohse
Cancer Research. 2006-04-01
Journal Articles
- Radical Versus Partial Nephrectomy for cT1 Renal Cell CarcinomaBoris Gershman, Stephen A Boorjian, Bradley C Leibovich, European Urology
- Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base Eur Urol 2013;63:823-9Eisenberg MS, Leibovich BC, Kim SP. Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al, Eur Urol, 7/2/2013
- Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristicsEisenberg MS, Leibovich BC, Kim SP, Cancer, 5/21/2013
- Join now to see all
Press Mentions
- Kidney CancerAugust 17th, 2024
- The Power of AI: Advanced Algorithm IDs Heart Issues Using Apple Watch DataNovember 23rd, 2022
- Study Shows Smartwatch EKG’s Ability to Accurately Detect Heart FailureNovember 15th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: